Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Obstetrics & Gynecology 1996;87:532-538
© 1996 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Benedetti-Panici, P
Right arrow Articles by Mancuso, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benedetti-Panici, P
Right arrow Articles by Mancuso, S

Articles

The pelvic retroperitoneal approach in the treatment of advanced ovarian carcinoma

P Benedetti-Panici, F Maneschi, G Scambia, G Cutillo, S Greggi, and S Mancuso

OBJECTIVE: To evaluate the feasibility, complications, and clinical role of pelvic cytoreduction using the retroperitoneal approach in the treatment of advanced ovarian cancer. METHODS: We studied 66 women with previously untreated advanced ovarian cancer who underwent pelvic retroperitoneal surgery. The possibility of achieving extrapelvic cytoreduction (residual disease less than 2 cm), involvement of the Douglas cul-de-sac or vesicouterine fold, or the presence of a frozen pelvis were indications for the retroperitoneal approach. Operative time, blood loss and transfusions, perioperative complications, and postoperative stay were analyzed prospectively. The performance status of each patient was assessed preoperatively and postoperatively. RESULTS: The pelvic retroperitoneal approach was used in 66 of 147 (45%) consecutive patients who underwent primary surgery with intent of cytoreduction. This approach was necessary in 60 of 94 (64%) patients with residual tumor less than 0.5 cm and contributed to achieving such a minimal residual disease in 36 of 38 (95%) stage IIB-IIIB and 58 of 109 (53%) IIIC-IV patients. Severe morbidity, but with no long-term sequelae, occurred in six (9%) patients. Before surgery, only ten (15%) of these patients had a performance status grade 0-1, 21 (32%) had grade 2, and 35 (53%) grade 3-4. After surgery, these figures were 52 (79%), 14 (21%), and 0, respectively. The 5-year survival rate was 37%, with a median survival and follow up time of 27 months (range 4-98) and 43 months, respectively. CONCLUSION: If the proper technique is used, complete pelvic cytoreduction is always feasible and morbidity is acceptable. In our series, it was necessary to approach the pelvis retroperitoneally in 64% of optimally cytoreduced patients, which suggests that this technique has an important clinical role in the treatment of patients with advanced ovarian cancer.


This article has been cited by other articles:


Home page
Ann. Surg. Oncol.Home page
R. Giannice, E. Foti, A. Poerio, E. Marana, S. Mancuso, and G. Scambia
Perioperative Morbidity and Mortality in Elderly Gynecological Oncological Patients ("=" BORDER="0">70 Years) by the American Society of Anesthesiologists Physical Status Classes
Ann. Surg. Oncol., February 1, 2004; 11(2): 219 - 225.
[Abstract] [Full Text] [PDF]


Home page
Obstet GynecolHome page
G. CUTILLO, F. MANESCHI, M. FRANCHI, R. GIANNICE, G. SCAMBIA, and P. BENEDETTI-PANICI
Early Feeding Compared With Nasogastric Decompression After Major Oncologic Gynecologic Surgery: A Randomized Study
Obstet. Gynecol., January 1, 1999; 93(1): 41 - 45.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American College of Obstetricians and Gynecologists.